Dr. Karim Fizazi and Dr. Bertrand Tombal presented a debate on “Hormone-Naive Metastatic Prostate Cancer Patients Should Get Chemotherapy and ADT as a Standard of Care” versus “ADT and AR Pathway Targeted Agents Still Have a Role in These Patients” at the 6th Symposium on the Treatment of Prostate Cancer (STOP-6), which was held in Lisbon, Portugal between October 14th and 16th 2016.

STOP-6 was accredited for CME by the European Accreditation Council for CME (UEMS-EACCME).

The meeting was organized by Bioscript and the Scientific Committee, composed of Professors Laurence Klotz (Chair), Noel Clarke, Karim Fizazi and Bertrand Tombal.

Funding to support this educational activity was provided by FERRING Pharmaceuticals. FERRING did not influence meeting content and the views expressed during the meeting represent only those of the faculty.

 

Keywords: de novo metastatic prostate cancer, ADT, Docetaxel

How to cite: Fizazi, Karim and Tombal, Bertrand. “Prostate Cancer Patients Should/Should Not Get Chemo and ADT as a Standard of Care” Grand Rounds in Urology. October 14-16, 2016. Accessed Apr 2020. https://grandroundsinurology.com/debate-prostate-cancer-patients-shouldshould-not-get-chemo-adt-standard-care

This presentation was made at the 6th Symposium on the Treatment of Prostate Cancer (STOP-6), which was held in Lisbon, Portugal between the 14th and 16th October.

STOP-6 was accredited for CME by the European Accreditation Council for CME (UEMS-EACCME).

The meeting was organized by Bioscript and the Scientific Committee, composed of Professors Laurence Klotz (Chair), Noel Clarke, Karim Fizazi and Bertrand Tombal.

Funding to support this educational activity was provided by FERRING Pharmaceuticals. FERRING did not influence meeting content and the views expressed during the meeting represent only those of the faculty.